27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Ninety-four percent of hospices and 72% of PC programs had served at least one patient with a primary diagnosis of dementia within the past year. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
There were 13,700 beneficiaries with full-year enrollment in MA (6,046) or TM (7,724), 518 with ADRD and 13,252 without ADRD. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of members initiated on an antimuscarinic OAB medication, 31.1% had a drug-drug or drug-disease or syndrome interaction. 5 key findings →
Participants: 66,275 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In FFS, AD incidence (2008-2018) decreased (138 to 104); MCI incidence increased (8 to 47), but the sum (MCI + AD) was relatively stable (146 to 151). 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Among PWD with Medicaid, out-of-pocket costs for nursing homes and assisted living facilities were significantly higher (60%) compared to those TM (33%) and MA (30%). 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
For patients with serious comorbidities, diabetes management guidelines recommend more relaxed glycemic targets (glycosylated hemoglobin [HbA1c] <8-8.5% rather than <7%) and cautious use of agents known to cause hypoglycemia. 5 key findings →
Participants: 216,839 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In this study on Medicare patients with AF, Black race, low-income subsidy, and dual eligibility were found to be associated with delayed OAC initiation, suggesting potential disparities in the care of AF with timely OAC treatment. 5 key findings →
Participants: 446,441 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Dual-related differences were significantly larger than race/ethnicity differences in PAC transitions. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Of 2 197 732 beneficiaries enrolled in D-SNPs in 2021, 881 736 (40.1%) were living in counties with aligned enrollment available and 251 305 (11.4%) enrolled. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Medicare-funded home health care (HH) is a crucial resource helping Persons with Dementia (PwD) meet their care needs while aging in place. 1 key finding →
Participants: 907,553 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In the base-case analysis from the healthcare perspective, SoC was more clinically effective than BSC with a cost per QALY of $5211. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Addressing disparities related to Alzheimer's disease and Alzheimer's disease related dementias (AD/ADRD) is a priority for policymakers, practitioners, and researchers. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Semantic dementia (SD) is a clinical subtype of frontotemporal dementia characterized by impaired word comprehension and semantic memory, and occurs nearly always sporadically. 1 key finding →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The project is expected to generate evidence on the effectiveness, feasibility, and cost-effectiveness of multidomain interventions implemented across diverse real-world settings, including community, hospital, and long-term care. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The demographic transition during the recent decades has resulted in an increase in older adults globally. 2 key findings →
Design: narrative review Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Identifying strategies to enhance patient engagement and to control healthcare costs promotes a responsive and efficient healthcare system. 4 key findings →
Participants: 401 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Misconceptions were common: 38% of participants equated ACP exclusively with decisions to forgo active treatment, and many conflated ACP with current rather than future-oriented care planning. 5 key findings →
Design: cross-sectional Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
ACP is linked to lower EOL spending and a shift from inpatient to outpatient ADRD care; structured ACP delivery should be considered. 1 key finding →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
An assessment of the value of lecanemab for patients living with Alzheimer's disease (AD) and their care partners provides them and their health-care providers important information for deciding treatment initiation. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
A nationwide ACP program in the primary care setting is a cost-effective or cost-saving intervention compared to usual care in a population at-risk of developing dementia. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Recent efforts have revealed that numerous protein-coding messenger RNAs have natural antisense transcript partners, most of which seem to be noncoding RNAs. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source
The NLRP3 inflammasome is a critical component of the innate immune system that mediates caspase-1 activation and the secretion of proinflammatory cytokines IL-1β/IL-18 in response to microbial infection and cellular damage. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
Metabolic endotoxemia is a condition in which blood lipopolysaccharide (LPS) levels are elevated, regardless of the presence of obvious infection. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
ADODs will cost the world economy 14 513 billion international dollars (INT$, measured in the base year 2020; 95% uncertainty interval [UI] 12 106-17 778) from 2020 to 2050, equivalent to 0·421% (95% UI 0·351-0·515) of annual global GDP. 5 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source
10 of the 705 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →